Niraparib
Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. Niraparib is specifically metabolized by carboxylesterase 1 via amide hydrolysis to an acid metabolite
General
Type : Not AlphaBeta Hydrolase target, Drug, Imidazole, Piperidine, Carboxamide, Indazole
Chemical_Nomenclature : 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
Canonical SMILES : C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N
InChI : InChI=1S\/C19H20N4O\/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14\/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)\/t14-\/m1\/s1
InChIKey : PCHKPVIQAHNQLW-CQSZACIVSA-N
Other name(s) : MK4827 || 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide || 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide || CHEBI:176844 || RefChem:57941 || MK-4827 || CHEMBL1094636
MW : 320.4
Formula : C19H20N4O
CAS_number : 1038915-60-4
PubChem : 24958200
UniChem : PCHKPVIQAHNQLW-CQSZACIVSA-N
Target
Structures : No structure
Families : Carb_B_Chordata
References (8)
| Title : Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib - Lewis_2026_CPT.Pharmacometrics.Syst.Pharmacol_15_e70182 |
| Author(s) : Lewis GJ , Jewell RC , Krishnatry AS , Taskar KS |
| Ref : CPT Pharmacometrics Syst Pharmacol , 15 :e70182 , 2026 |
| Abstract : |
| PubMedSearch : Lewis_2026_CPT.Pharmacometrics.Syst.Pharmacol_15_e70182 |
| PubMedID: 41531282 |
| Title : Physiologically-Based Pharmacokinetic Modeling of the PARP Inhibitor Niraparib - Lewis_2026_CPT.Pharmacometrics.Syst.Pharmacol_15_e70182 |
| Author(s) : Lewis GJ , Jewell RC , Krishnatry AS , Taskar KS |
| Ref : CPT Pharmacometrics Syst Pharmacol , 15 :e70182 , 2026 |
| Abstract : |
| PubMedSearch : Lewis_2026_CPT.Pharmacometrics.Syst.Pharmacol_15_e70182 |
| PubMedID: 41531282 |
| Title : Cytochrome P450 inhibitor\/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting - Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| Author(s) : Rimel BJ , Chase DM , Perhanidis J , Ghazarian AA , Du EX , Wang T , Song J , Golembesky AK , Hurteau JA , Kalilani L , Salani R , Monk BJ |
| Ref : Gynecologic Oncology Rep , 51 :101332 , 2024 |
| Abstract : |
| PubMedSearch : Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| PubMedID: 38362364 |
| Title : Cytochrome P450 inhibitor\/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting - Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| Author(s) : Rimel BJ , Chase DM , Perhanidis J , Ghazarian AA , Du EX , Wang T , Song J , Golembesky AK , Hurteau JA , Kalilani L , Salani R , Monk BJ |
| Ref : Gynecologic Oncology Rep , 51 :101332 , 2024 |
| Abstract : |
| PubMedSearch : Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| PubMedID: 38362364 |
| Title : Cytochrome P450 inhibitor\/inducer treatment patterns among patients in the United States with advanced ovarian cancer who were prescribed or were eligible for poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitors in the first-line maintenance setting - Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| Author(s) : Rimel BJ , Chase DM , Perhanidis J , Ghazarian AA , Du EX , Wang T , Song J , Golembesky AK , Hurteau JA , Kalilani L , Salani R , Monk BJ |
| Ref : Gynecologic Oncology Rep , 51 :101332 , 2024 |
| Abstract : |
| PubMedSearch : Rimel_2024_Gynecol.Oncol.Rep_51_101332 |
| PubMedID: 38362364 |
| Title : Molecular interaction of anti-cancer ligands with human brain acetylcholinesterase - Shakil_2020_J.Biomol.Struct.Dyn__1 |
| Author(s) : Shakil S |
| Ref : J Biomol Struct Dyn , :1 , 2020 |
| Abstract : |
| PubMedSearch : Shakil_2020_J.Biomol.Struct.Dyn__1 |
| PubMedID: 33089743 |
| Title : Molecular interaction of anti-cancer ligands with human brain acetylcholinesterase - Shakil_2020_J.Biomol.Struct.Dyn__1 |
| Author(s) : Shakil S |
| Ref : J Biomol Struct Dyn , :1 , 2020 |
| Abstract : |
| PubMedSearch : Shakil_2020_J.Biomol.Struct.Dyn__1 |
| PubMedID: 33089743 |
| Title : Molecular interaction of anti-cancer ligands with human brain acetylcholinesterase - Shakil_2020_J.Biomol.Struct.Dyn__1 |
| Author(s) : Shakil S |
| Ref : J Biomol Struct Dyn , :1 , 2020 |
| Abstract : |
| PubMedSearch : Shakil_2020_J.Biomol.Struct.Dyn__1 |
| PubMedID: 33089743 |